Mutual of America Capital Management LLC Increases Stake in Kenvue Inc. (NYSE:KVUE)

Mutual of America Capital Management LLC lifted its stake in Kenvue Inc. (NYSE:KVUE) by 1.5% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 322,208 shares of the company’s stock after buying an additional 4,704 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Kenvue were worth $7,453,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of KVUE. Riverview Trust Co purchased a new stake in Kenvue in the 3rd quarter worth $30,000. Ashton Thomas Securities LLC bought a new position in Kenvue during the third quarter valued at approximately $35,000. Studio Investment Management LLC grew its holdings in Kenvue by 52.1% during the 2nd quarter. Studio Investment Management LLC now owns 2,468 shares of the company’s stock valued at $45,000 after buying an additional 845 shares in the last quarter. Deseret Mutual Benefit Administrators increased its stake in Kenvue by 49.7% in the 3rd quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company’s stock worth $45,000 after acquiring an additional 651 shares during the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA purchased a new stake in shares of Kenvue during the 2nd quarter worth approximately $61,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

Shares of KVUE stock opened at $23.73 on Tuesday. The stock has a 50 day moving average price of $22.77 and a 200 day moving average price of $20.71. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $24.13. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The firm has a market capitalization of $45.50 billion, a P/E ratio of 43.15, a P/E/G ratio of 2.16 and a beta of 1.36.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.01. The business had revenue of $3.90 billion during the quarter, compared to the consensus estimate of $3.92 billion. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The business’s revenue for the quarter was down .4% compared to the same quarter last year. During the same period last year, the company earned $0.31 earnings per share. As a group, sell-side analysts predict that Kenvue Inc. will post 1.07 earnings per share for the current year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th will be paid a $0.205 dividend. The ex-dividend date is Wednesday, November 13th. This represents a $0.82 dividend on an annualized basis and a yield of 3.46%. Kenvue’s dividend payout ratio is currently 149.09%.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. JPMorgan Chase & Co. raised their target price on shares of Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Jefferies Financial Group initiated coverage on shares of Kenvue in a report on Tuesday, September 24th. They issued a “buy” rating and a $27.00 price target for the company. Bank of America boosted their price objective on Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research note on Tuesday, October 22nd. Finally, Royal Bank of Canada downgraded Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price objective on the stock. in a research report on Tuesday, September 24th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $22.64.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.